Clinical evolution of a severe asthmatics group in the use of immunobiological therapy in a Brazilian Public Hospital.

Lêda Maria Rabelo Rebecca Saray Marchesini Stival Diogo Drevenowski Joel Serafini Giovanna Lemes Leão Matheus Fernando Rietter Quintino Ferreira Fabio Marcelo Costa

Published in: Revista da Associacao Medica Brasileira (1992) (2021)

The use of omalizumab and mepolizumab as additional therapy in SA provided a significant improvement in the ACT and allowed the dose reduction of systemic corticosteroids, without significant improvement in FEV1 and in the frequency of severe exacerbations.

Keyphrases

healthcare
early onset
cystic fibrosis
mental health
adverse drug
bone marrow